.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,838,563

« Back to Dashboard

Details for Patent: 7,838,563

Title:Compounds, formulations, and methods for ameliorating telangiectasias
Abstract: Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an .alpha.-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.
Inventor(s): DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ), Powala; Christopher (Radnor, PA)
Assignee: Galderma Laboratories Inc. (Fort Worth, TX)
Filing Date:Jun 08, 2006
Application Number:11/449,079
Claims:1. A method of ameliorating a telangiectasia, the method comprising topically administering to an affected area of skin of a subject in need thereof a therapeutically effective amount of a composition comprising at least one .alpha.-adrenergic receptor agonist, a pharmaceutically acceptable salt thereof, or a combination thereof.

2. A method in accordance with claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is an agonist selective for an .alpha.1-adrenergic receptor.

3. A method in accordance with claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is an agonist selective for an .alpha.2-adrenergic receptor.

4. A method in accordance with claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is a non-selective .alpha.-adrenergic receptor agonist.

5. A method in accordance with claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is brimonidine.

6. The method in accordance with claim 1, wherein the composition further comprises at least one pharmaceutically acceptable carrier.

7. The method in accordance with claim 6, wherein the composition is of a form selected from the group consisting of a spray, a low-viscosity aqueous liquid, an alcoholic liquid, a mist, an aerosol, a lotion, a gel, a cream, an ointment, a foam, a paste, an unguent, an emulsion, a liposomal suspension, a colloid and a combination thereof.

8. The method in accordance with claim 1, wherein the therapeutically effective amount for amelioration of a telangiectasia is an amount locally effective for amelioration of the telangiectasia.

9. The method in accordance with claim 1, wherein the at least one .alpha.-adrenergic receptor agonist, a pharmaceutically acceptable salt thereof, or a combination thereof is a first active ingredient, and the composition further comprises a second active ingredient.

10. The method in accordance with claim 9, wherein the second active ingredient is selected from the group consisting of an antibiotic, a non-antibiotic chemically modified tetracycline, a steroid, a retinoid, and an anti-fungal agent.

11. The method in accordance with claim 10, wherein the antibiotic is selected from the group consisting of clindamycin, doxycycline, erythromycin, metronidazole, sulfacetamide and tetracycline.

12. The method in accordance with claim 9, wherein the second active ingredient is selected from the group consisting of azelaic acid, benzoyl peroxide, isotretinoin, an antibiotic, a pharmaceutically acceptable salt thereof and a combination thereof.

13. The method in accordance with claim 1, further comprising systemically administering an antibiotic.

14. The method in accordance with claim 13, wherein the antibiotic is selected from the group consisting of clindamycin, doxycycline, erythromycin, metronidazole, sulfacetamide and tetracycline.

15. The method of claim 1, wherein the telangiectasia is not associated with rosacea.

16. The method of claim 1 wherein the telangiectasia is a telangiectasia associated with at least one of age, sun exposure, alcohol use, scleroderma, hereditary hemorrhagic telangiectasia (Olser-Rendu syndrome), Ataxia-Telangiectasia, spider angioma, cutis marmorata telangiectasia congenita, Bloom syndrome, Klippel-Trenaunay-Weber syndrome, Sturge-Weber disease, Xeroderma pigmentosa, Nevus flammeus, Generalized essential telangiectasias (GET), angioma serpiginosum, ataxia telangiectasia, spider naevi, CREST Syndrome, hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu Syndrome), ataxia-telangiectasia, basal cell carcinoma, scleroderma, unilateral nevoid telangiectasia, and cutis marmorata telangiectatica congenita.

17. The method of claim 1 wherein the telangiectasia is a telangiectasia associated with rosacea.

18. A method in accordance with claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is selected from the group consisting of oxymetazoline, tetrahydrozoline, naphazoline, xylometazoline, phenylephrine, methoxamine, mephentermine, metaraminol, midodrine, epinephrine, and norepinephrine.

19. A method in accordance with claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is oxymetazoline.

20. A method of ameliorating [visible small, red, purple, or blue surface blood vessels] swelling of blood vessels, enlarged, dilated and/or visible spider veins, and red, purple or blue patches on the skin resulting from dilated blood vessels associated with telangiectasia, the method comprising topically administering to an affected area of skin of a subject in need thereof a therapeutically effective amount of a composition comprising at least one .alpha.-adrenergic receptor agonist, a pharmaceutically acceptable salt thereof, or a combination thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc